Catherine Soo

Catherine has a background in pharmacology and earned her Ph.D. in Pharmacology and Experimental Pathology from the London Hospital Medical College (*now* Barts and The London School of Medicine and Dentistry), University of London, U.K. Catherine began her career at Health Canada in 2011 as a Regulatory Project Manager within the Therapeutic Products Directorate (TPD). Shortly after, Catherine moved into an Assessment Officer role within the Division of Biopharmaceutics Evaluation (DBE), where she reviewed comparative bioavailability studies submitted in pharmaceutical drug applications (generic and innovative). In 2015, Catherine joined the Biologics and Genetic Therapies Directorate (BGTD) as a Senior Clinical Evaluator in the Clinical Trials Division and later, in 2017, joined the pre-market review area within the Clinical Evaluation Division – Hematology/Oncology (CED-HO). Her key responsibility includes the evaluation of clinical data submitted to support innovative biologic drugs and biosimilars. Catherine therefore has clinical review experience in both the pharmaceutical and biologics areas as well as has knowledge of the Canadian regulatory requirements for filing.